Novel Molecular Targets of Dezocine and Their Clinical Implications

@article{Liu2014NovelMT,
  title={Novel Molecular Targets of Dezocine and Their Clinical Implications},
  author={Renyu Liu and Xi-Ping Huang and Alexei Yeliseev and Jin Xi and Bryan L. Roth},
  journal={Anesthesiology},
  year={2014},
  volume={120},
  pages={714–723}
}
Background:Although dezocine is a partial &mgr;-opioid receptor agonist, it is not a controlled substance. Thus, the characterization of the molecular targets of dezocine is critical for scientific and clinical implications. The goal of this study is to characterize molecular targets for dezocine and determine their implications. Methods:A binding screen for dezocine was performed on 44 available receptors and transporter proteins. Functional assays for the novel targets were performed along… 
Dezocine is a Biased Ligand without Significant Beta-Arrestin Activation of the mu Opioid Receptor
TLDR
A possible explanation of why dezocine is not addictive or at least less addictive than other commonly used opioids is provided and intranasal administration offers an alternative strategy for its potential clinical applications.
Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist
TLDR
It is identified that the analgesic effect of Dezocine was a result of action at both the κ and μ opioid receptors, and was a κ partial agonist and μpartial agonist.
Antidepressant-like effects of dezocine in mice: involvement of 5-HT1A and κ opioid receptors
TLDR
Considering the well-documented analgesic property of dezocine, it may be useful to treat pain and depression comorbidity and may have antidepressant-like effects.
Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase
TLDR
The inhibitory effect of dezocine on triple-negative breast cancer (TNBC) cells is demonstrated, and the underlying molecular mechanism is determined, suggesting that both deZocine and NAMPT might represent novel therapeutic targets for TNBC.
Dezocine Alleviates Morphine-Induced Dependence in Rats.
TLDR
Dezocine could potentially be used to alleviate opioid dependence due to the unique molecular target profile different from buprenorphine, and might have important value in studying the mechanisms of morphine dependence and developing novel therapeutic approaches.
Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition
TLDR
The findings reclassify dezocine as the first analgesic of the recently proposed MOR-NRI, and reveal its potential as an alternative to as well as concurrent use with morphine in treating pain.
Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain
TLDR
The combination of low-dose dezocine with morphine may prevent or delay the development of morphine tolerance in a rat model of bone cancer pain and the regulation of opioid receptor expression in the PAG and spinal cord may be part of the mechanism.
Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model
TLDR
It is concluded that the administration of dezocine promotes BMDC maturation and inhibits tumor metastasis through elevating CD8+ T cell proliferation and cytotoxicity.
Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies.
TLDR
An overview of potential analgesic therapies in various stages of development, which may become clinically relevant in the near future are provided.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Crystal structure of the μ-opioid receptor bound to a morphinan antagonist
TLDR
The 2.8 Å crystal structure of the mouse µ-OR in complex with an irreversible morphinan antagonist is described, revealing high-resolution insights into opioid receptor structure that will enable the application of structure-based approaches to develop better drugs for the management of pain and addiction.
Structure of the human k-opioid receptor in complex with JDTic
TLDR
Analysis of site-directed mutagenesis and ligand structure–activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for k- OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human k-OR.
Anesthetic Potency of Dezocine and Its Interaction with Morphine in Rats
TLDR
A new partial agonist–antagonist analgesic drug, dezocine, was evaluated in rats for its anesthetic potency using a MAC-reduction model and suggests that dezOCine acts primarily on the same receptor (mu) as morphine and that this receptor activity is further modulated by effects of deZocine on a second opioid receptor.
Pharmacological profiles of opioid ligands at Kappa opioid receptors
TLDR
These results elucidate the relative activities of a set of opioid ligands at κ-opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of these opioid ligand at this receptor.
LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake
TLDR
Mutagenesis experiments on human SERT and DAT indicate that both the desipramine-binding site and its inhibition mechanism are probably conserved in the human neurotransmitter transporters.
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
  • B. Roth, K. Baner, R. Rothman
  • Biology, Psychology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
TLDR
Salvinorin A is the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist for kappa opioid receptors, and may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders).
Dezocine: a novel drug to prevent fentanyl-induced cough during general anesthesia induction?
TLDR
There is no evidence support for the claim that dezocine counteracted the action of fentanyl by a central gating mechanism of cough suppression, predominantly via C-fiber receptors, or, whether dezOCine inhibited the release of histamine by antagonizing and suppressing cough reflex.
Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist
  • B. Roth, K. Baner, R. Rothman
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2002
TLDR
Salvinorin A is the first naturally occurring nonnitrogenous opioid-receptor subtype-selective agonist for κ opioid receptors and may represent novel psychotherapeutic compounds for diseases manifested by perceptual distortions (e.g., schizophrenia, dementia, and bipolar disorders).
Ventilatory and Analgesic Effects of Dezocine in Humans
TLDR
Dezocine is an effective analgesic with morphine-like effects in human subjects and appears to be a slightly more potent analgesic than morphine in identical clinical doses (0.15 mg/kg).
...
...